Research
UK Cardio-Oncology Research Network
We want to promote multi-centre UK cardio-oncology research to change clinical outcomes for our patients, by ensuring that the research is well designed and collaborative, whilst maximising recruitment by linking researchers with clinicians and patients.
- researchers ‘advertise’ interests, expertise and access to patient groups
- central point for identification of potential collaborators
- please contact us via research@BC-OS.org
Broad representation
- clinical trials, data and basic science - we are actively seeking more oncology/haematology research links - the KEY TO SUCCESS!
- multi-centre studies and successful funding applications
- expansion of cardio-oncology registries
- incorporation of translational science in clinical studies where appropriate
- optimise use of electronic data linkage
Cardio-Oncology
Research Centres
Aberdeen
Belfast
Edinburgh
Glasgow
Leicester
Liverpool
London
Manchester
Middlesbrough
Contact research@BC-OS.org or use the details below to get involved in cardio-oncology research
- Aberdeen
-
Prof Dana Dawson and team, University of Aberdeen
Magnetic Resonance Spectroscopy Assessment of Cardiac and Skeletal Muscle Following Anthracycline Based Treatment for Breast Cancer. BCOS is part of the BHF CRC which provides infrastructure to support clinical research in UK, via coordination of activity and prioritisation of research identified as important by patients and other stakeholders.
- Edinburgh
-
Dr Peter Henriksen and team, NHS Lothian/University of Edinburgh
Cardiac CARE: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity
-
- Glasgow
-
Dr Ninian Lang and team, University of Glasgow
Prospective Characterisation of CV Effects of VEGF Inhibitors (EndoTOX)
Prospective Characterisation of CV Effects of BRAF/MEK Inhibitors in Melanoma (BioCOBRA)
FDG-PET Assessment of Immunotherapy/VEGFi Inflammatory Atheroma (BioCAPRI)
Cardiotoxicity of Carfilzomib: Stress Perfusion Magnetic Resonance Assessment
Clonal Haematopoiesis as a Risk Factor for Cardiotoxicity of Cancer Therapy
-
- Belfast
-
Prof Mark Harbinson and team, Queen’s University, Belfast
Cancer and heart disease demographics. Linkage of NI cancer registry with NI hospital diagnostic codes
-
- Middlesbrough
-
Dr David Austin and team, South Tees Academic Cardiovascular Unit/South Tees NHS Foundation Trust
Preventing cardiotoxicity in patients with breast cancer and lymphoma: a multicentre randomised controlled trial (PROACT)
- Liverpool
-
Dr Rebecca Dobson, Dr David Gent and team, Liverpool Heart and Chest Hospital
Patient-derived pluripotent stem cells to understand mechanisms and preventive strategies for anthracycline cardiotoxicity.Characterisation of short and long-term adverse cardiovascular effects of stem cell transplants to improve risk-stratification.
- Manchester
-
Prof Chris Miller and Prof John Radford, University of Manchester/NIHR Manchester Biomedical Research Centre (BRC)
Living with and Beyond Cancer: Improving Cardiovascular Health (cardio-onc registry, n=2,500 long-term data linkage)
- Leicester
-
Dr David Adlam, University of Leicester
VICORI: Virtual Cardio-Oncology Research Initiative. Data linkage between National Cancer Registration and Analysis Service (NCRAS) and the six National Cardiovascular disease audits held by the National Institute for Cardiovascular Outcome Research (NICOR)
- London
-
Prof Charlotte Manisty, Mark Westwood, Malcolm Walker, Arjun Ghosh, Tom Crake and team, Barts/UCL
HER2-targeted cardiotoxicity: RCT of withdrawal of HF meds in recovered LV. Optimising screening
Fluoropyrimidines: Prospective risk prediction study, mechanistic study
Linked data analysis (VICORI)
CAR-T cardiotoxicity: Longitudinal Characterisation
Cancer-CV associations in UK Biobank
Pharmacoepidemiology of CV drugs in patients with cancer
AI-based screening for cardiotox (prospective assessment)
Dr Alex Lyon and team, Royal Brompton and Harefield NHS Trust
CV toxicities of immunotherapy
AI in cardio-oncology
ESC Guidelines
Prof Theresa McDonagh, Dr Clare Bannister and team, Kings, London
Biomarkers and risk prediction for anthracycline cardiotoxicity
Current UK multi-centre cardio-oncology research
- Virtual Cardio-Oncology Research Initiative
-
VICORI
This joint British Heart Foundation and Cancer Research UK funded project provides a large-scale linked dataset comprising the National Cancer Registration and Analysis Service (NCRAS) and the six National Cardiovascular disease audits held by the National Institute for Cardiovascular Outcome Research (NICOR). The data will be used to investigate differences in treatments and outcomes between patients with cancer, cardiovascular disease, or both. VICORI welcomes collaboration from other institutions and for further applications and data access requests please visit their website. Chief Investigator: Dr David Adlam (University of Leicester). - CARDIAC CARE
-
CARDIAC CARE
Multi-centre randomised controlled trial of troponin-guided therapy to prevent anthracycline-related cardiac toxicity in breast cancer and lymphoma patients receiving anthracycline adjuvant therapy. Chief Investigator: Dr Peter Henriksen (University of Edinburgh). Funding NIHR EME and BHF. - PRevention Of Anthracycline Cardiac Toxicity
-
PROACT
Multi-centre, prospective, randomised, open-label, blinded end-point, superiority trial to test the effectiveness of Enalapril in preventing cardio-toxicity in patients with breast cancer undergoing anthracycline chemotherapy. Chief Investigator: Dr David Austin (South Tees NHS Trust). Funding NIHR.
- Implementation of Cardio-Oncology Training for Cardiology Fellows
-
JACC Journals › JACC: CardioOnc › Archives › Vol. 2 No. 5
An interesting viewpoint co-authored by Arjun Ghosh - AHA Cardio-Oncology: Vascular and Metabolic Perspectives 2019
-
A Scientific Statement From the American Heart Association.
Circulation. 2019;139:e579–e602. DOI: 10.1161/CIR.0000000000000641 - ESC Position paper on cancer treatments and cardiovascular toxicity 2016
-
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines.
European Journal of Heart Failure (2017) 19, 9–42 -
Cardiovascular Toxicity Induced by Chemotherapy, Targeted Agents and Radiotherapy:
ESMO Clinical Practice Guidelines -
Pellentesque fermentum dolor. Aliquam quam lectus, facilisis auctor, ultrices ut, elementum vulputate, nunc.
Annals of Oncology 23 (Supplement 7): vii155–vii166, 2012
- ICOS podcasts
-
Arjun, Ashutosh and Amyloidosis, Dr. Baliga's "Got Knowledge Doc", Dr. Susan Dent ASCO daily news...
ICOS podcast library - European Society of Cardiology cardio-oncology webinars
-
ESC webinars - click the link to see the webinar index - then choose cardio-oncology to filter
ESC webinar index - ESC Cardio-Oncology Audio Interviews
-
04/01/2021 - Long-term survivorship programmes - reality or fiction?
14/12/2020 - How can cardiologists and hematologists collaborate to improve cardio-oncology structures?
09/11/2020 - Cancer and Vascular Toxicity
13/03/2020 - Immunotherapy: the new tsunami
06/01/2020 - Cardiac Imaging in Cancer patients
02/12/2019 - Cancer and Heart failure: from prevention to treatment
21/10/2019 - When and why do we need a cardio-oncology service?
The index of interviews is here.